Larimar Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Larimar Therapeutics has a total shareholder equity of $198.4M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $219.0M and $20.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$203.71m |
| Equity | US$198.40m |
| Total liabilities | US$20.62m |
| Total assets | US$219.02m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ZA71's short term assets ($213.3M) exceed its short term liabilities ($16.3M).
Long Term Liabilities: ZA71's short term assets ($213.3M) exceed its long term liabilities ($4.3M).
Debt to Equity History and Analysis
Debt Level: ZA71 is debt free.
Reducing Debt: ZA71 has no debt compared to 5 years ago when its debt to equity ratio was 33.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZA71 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: ZA71 has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 7.4% each year.